Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gastrointestinal microbiota and mucosa constitute a complex biological system essential for maintaining systemic homeostasis and immune regulation. The microbiota comprises a diverse community of bacteria, archaea, fungi, and viruses, while the mucosa acts as a multi-layered barrier consisting of epithelial cells, a mucus layer, and underlying immune cells (Thursby & Juge, 2017, Biochem J). This system is responsible for the fermentation of non-digestible dietary fibers into short-chain fatty acids (SCFAs), the synthesis of vitamins, and the competitive exclusion of pathogenic microorganisms (Lynch & Pedersen, 2016, NEJM). Furthermore, the intestinal mucosa facilitates oral tolerance by preventing inappropriate immune responses to commensal microbes and food antigens while maintaining the ability to mount defenses against pathogens (Belkaid & Hand, 2014, Cell). Dysfunction within this system, often characterized by reduced microbial diversity (dysbiosis) and increased epithelial permeability, is a hallmark of numerous pathologies, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic syndrome (Turner, 2009, Nat Rev Immunol). Pharmacological and therapeutic interventions targeting this environment include probiotics and prebiotics to modulate microbial composition, as well as aminosalicylates and biologics designed to promote mucosal healing and restore barrier integrity (Okumura & Takeda, 2017, Exp Mol Med).
Modulation of microbial populations, restoration of epithelial barrier function, suppression of mucosal inflammation, and competitive inhibition of pathogens.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal microbiota and mucosa.